skip to content

CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.